[HTML][HTML] “Positioning of Tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: an Italian and Spanish consensus paper”.
P Conte, E Ciruelos, G Curigliano, M De Laurentiis… - The Breast, 2024 - Elsevier
Introduction Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and
antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2 …
antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2 …